{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T09:06:42Z","timestamp":1762506402661,"version":"3.44.0"},"reference-count":16,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Reports"],"accepted":{"date-parts":[[2014,8,1]]},"abstract":"<jats:p>Recent reports suggest that topical imiquimod cream is an effective treatment option for certain types of melanomas. No reports exist on the efficacy of using imiquimod cream to treat melanoma located on the plantar surface of the foot. We present two patients with a melanoma of the foot who had residual melanoma following surgical excision with acceptable margins. The patients were then treated with topical imiquimod for 8\u2005weeks after which a repeat biopsy of the affected region showed no evidence of residual melanoma in situ. The use of topical imiquimod cream should be considered in the management of residual melanoma in situ of the plantar surface of the foot.<\/jats:p>","DOI":"10.1136\/bcr-2014-203826","type":"journal-article","created":{"date-parts":[[2014,8,21]],"date-time":"2014-08-21T08:39:22Z","timestamp":1408610362000},"page":"bcr2014203826","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["Use of imiquimod for residual acral melanoma"],"prefix":"10.1136","volume":"2014","author":[{"given":"Gloria R","family":"Sue","sequence":"first","affiliation":[{"name":"Yale University School of Medicine, New Haven, Connecticut, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Allison","family":"Hanlon","sequence":"additional","affiliation":[{"name":"Yale University School of Medicine, New Haven, Connecticut, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rossitza","family":"Lazova","sequence":"additional","affiliation":[{"name":"Yale University School of Medicine, New Haven, Connecticut, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Deepak","family":"Narayan","sequence":"additional","affiliation":[{"name":"Section of Plastic Surgery, Yale University School of Medicine, New Haven, Connecticut, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2014,8,21]]},"reference":[{"key":"2025082722433736000_2014.aug21_1.bcr2014203826.1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4632.2010.04423.x"},{"key":"2025082722433736000_2014.aug21_1.bcr2014203826.2","doi-asserted-by":"publisher","DOI":"10.1038\/ni758"},{"key":"2025082722433736000_2014.aug21_1.bcr2014203826.3","first-page":"163","article-title":"Immunomodulation by imiquimod in patients with high-risk primary melanoma","volume":"321","author":"Narayan","year":"2011","journal-title":"J Invest Dermatol"},{"key":"2025082722433736000_2014.aug21_1.bcr2014203826.4","doi-asserted-by":"publisher","DOI":"10.1046\/j.0366-077X.2003.05637.x"},{"key":"2025082722433736000_2014.aug21_1.bcr2014203826.5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2004.05983.x"},{"key":"2025082722433736000_2014.aug21_1.bcr2014203826.6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2004.01452.x"},{"key":"2025082722433736000_2014.aug21_1.bcr2014203826.7","doi-asserted-by":"publisher","DOI":"10.1097\/00042728-200802000-00002"},{"key":"2025082722433736000_2014.aug21_1.bcr2014203826.8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4725.2010.01560.x"},{"key":"2025082722433736000_2014.aug21_1.bcr2014203826.9","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.144.7.943"},{"key":"2025082722433736000_2014.aug21_1.bcr2014203826.10","doi-asserted-by":"publisher","DOI":"10.1159\/000063904"},{"key":"2025082722433736000_2014.aug21_1.bcr2014203826.11","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0b013e328345e95e"},{"key":"2025082722433736000_2014.aug21_1.bcr2014203826.12","first-page":"302","article-title":"Regression of internal melanoma metastases following application of topical imiquimod to overlying skin","volume":"10","author":"Miller","year":"2011","journal-title":"J Drugs Dermatol"},{"key":"2025082722433736000_2014.aug21_1.bcr2014203826.13","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2010.338"},{"key":"2025082722433736000_2014.aug21_1.bcr2014203826.14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1993.tb15138.x"},{"key":"2025082722433736000_2014.aug21_1.bcr2014203826.15","doi-asserted-by":"crossref","first-page":"250","DOI":"10.6004\/jnccn.2009.0020","article-title":"Melanoma","volume":"7","author":"Coit","year":"2009","journal-title":"J Natl Compr Canc Netw"},{"key":"2025082722433736000_2014.aug21_1.bcr2014203826.16","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4725.2011.02043.x"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2014-203826","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T05:43:44Z","timestamp":1756359824000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2014-203826"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,21]]},"references-count":16,"alternative-id":["10.1136\/bcr-2014-203826"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2014-203826","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2014,8,21]]}}}